DRRX: DURECT Company Value to Net Income

Symbol and logo of brand DURECT (DRRX)

This daily price chart for DURECT Corporation (DRRX) on the GURU.Markets platform tracks the company developing epigenetic therapies for severe liver damage, where the indicator stands at -4.10. Business revenues will be based on insurance payouts for innovative injections that reduce patient mortality. The project's ultimate success relies on the results of Phase 3 larsucosterol trials and the robustness of the patent portfolio.

DRRX - DURECT P/E Multiple over the range 07/04/2022 - 09/27/2025

Comprehensive metric breakdowns and analytics for DURECT Corp (DRRX)

- price and consensus price forecast:
Stock Price DURECT|DRRX - Consensus Target
- market capitalization information:
Market Value DURECT Corp.|DRRX - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Single Share DURECT|DRRX - Book Capitalization|Market Capitalization to Book Value durect.com|DRRX - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Equity DURECT Corporation|DRRX - Long-Term Debt to Capital|Current Liabilities to Capital durect.com|DRRX - Company Debts|Debt to Net Assets Ratio DURECT Corp|DRRX - Company Long-Term Debts|Company Short-Term Indebtedness DURECT|Quick Ratio durect.com
- earnings and market ratios statistics:
DRRX - Company Net Income|Expected Net Income DURECT Corporation|DRRX - P/E Multiple|Projected Price to Earnings Ratio DURECT Corporation|DRRX - PEG Multiple|Enterprise Value to EBITDA Ratio DURECT Corporation|DRRX - Operating profit before deduction of amortization|Earnings per share for the last four quarters DURECT|DRRX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months durect.com|DRRX - Earnings growth in current year|Expected earnings per share growth for next year DURECT Corporation
- company sales and revenue statistics:
DRRX - Company Revenue|Company Expected Sales Volume durect.com|DRRX - Price-to-Revenue Ratio|Forward Price to Sales DURECT Corp.
Comprehensive company analysis:DURECT - DRRX
Brand item of DURECT

The P/E ratio determines the market value of a business relative to its annual net income, measuring the investment payback period assuming a constant level of earnings. For DURECT Corporation (DRRX), the price-to-earnings ratio trend reflects market confidence in the monetization of robotic bio-screening and AI platforms, allowing for an assessment of the premium the market currently prices into the efficiency of automated drug development within the current share price.

Key competitors

P/E Multiple Arrowhead Pharmaceuticals Inc|Price to Earnings Ratio MIRM (Mirum Pharma)|DVAX (Dynavax) - Company Value to Net Income|Price to Earnings Ratio Arbutus Biopharma ABUS|Business Payback Period Inventiva (IVA)|Gyre Therapeutics Inc - P/E Multiple|Business Payback Period Assembly Biosciences Inc ASMB|GALT (Galectin Therapeutics, Inc.) - Price to Earnings Ratio|GNFT (Genfit SA) - Price to Earnings Ratio|ALGS (Aligos Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings biovieinc.com BIVI|Price to Earnings Ratio Galmed Pharmaceuticals Ltd (GLMD)|NDRA (ENDRA Life Sciences Inc.) - Company Value to Net Income|P/E Multiple HEPA (Hepion Pharmaceuticals)